Kling Biotherapeutics to Present Discoveries on its Primary B-Cell Screening Platform at the ESMO Targeted Anticancer Therapies Congress

• Kling reports on advancing pipeline of therapeutic antibodies targeting novel antigens discovered with its best-in-class B-cell screening platform, Kling-Select
• Progress on in vitro and in vivo validation of two highly specific tumor antigens is reported: CD43s, a sialylated-glyco epitope, and U5snRNP200, an ectopically expressed antigen highly specific for AML blast.
• Lead program KBA1412 is advancing in a Phase 1 clinical study, targeting advanced solid malignant tumors

Amsterdam, NLD – 22 February 2024 – Kling Biotherapeutics (“Kling” or “the Company”), a clinical stage biotech company developing antibody-based drugs against targets identified from its primary B-cell screening platform, today announces that it will be presenting findings demonstrating the power of its clinically validated, best-in-class, B cell screening platforms, Kling-Select and Kling-Evolve, at the ESMO Targeted Anticancer Therapies Congress, in Paris, France on 26 February.